Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Puri is an accomplished leader and financial sector veteran with over four decades of experience
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Exploring new opportunities within the fast-growing market of microfluidics
The TPE Tourniquet and TPE Esmark Bandages are renowned for their single-use design,
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Subscribe To Our Newsletter & Stay Updated
